ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.80
      0.02%
      Bitcoin
      65,123.40
      -0.02%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      10/11/20234:26PMBusiness WireIncyte präsentiert positive 52-Wochen-Daten aus Phase-2b-Studie zur Evaluierung von Povorcitinib (INCB54707) bei Patienten mit großflächiger, nicht segmentaler VitiligoNASDAQ:INCYIncyte Corporation
      10/11/202312:35PMBusiness WireIncyte annonce des données positives à 52 semaines d'une étude de Phase 2b évaluant povorcitinib (INCB54707) chez des patients atteints de vitiligo non segmentaire généraliséNASDAQ:INCYIncyte Corporation
      10/11/202310:30AMBusiness WireNew Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo PatientsNASDAQ:INCYIncyte Corporation
      10/11/20239:15AMBusiness WireIncyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of ClarityNASDAQ:INCYIncyte Corporation
      10/11/20238:15AMBusiness WireIncyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoNASDAQ:INCYIncyte Corporation
      10/10/20234:45PMGlobeNewswire Inc.Knight Therapeutics Announces Regulatory Submission of Pemigatinib in BrazilNASDAQ:INCYIncyte Corporation
      10/10/20238:00AMBusiness WireIncyte to Report Third Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
      10/04/20233:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      10/04/202312:01PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      10/03/20235:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      10/03/20234:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      10/03/20234:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      09/29/202310:31PMBusiness WireIncyte präsentiert mehrere Studien zu seinem Dermatologie-Portfolio auf dem European Academy of Dermatology and Venereology (EADV) Congress 2023NASDAQ:INCYIncyte Corporation
      09/29/202310:31PMBusiness WireIncyte présentera de multiples études de son portefeuille dermatologique au congrès 2023 de l’Académie européenne de dermatologie et de vénérologie (EADV)NASDAQ:INCYIncyte Corporation
      09/29/20231:43PMBusiness WireIncyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) CongressNASDAQ:INCYIncyte Corporation
      09/12/20235:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
      09/06/20234:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      09/01/20235:43PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      08/22/20238:00AMBusiness WireIncyte to Present at Upcoming Investor ConferencesNASDAQ:INCYIncyte Corporation
      08/14/20234:39PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:INCYIncyte Corporation
      08/03/20234:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      08/01/20234:49PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:INCYIncyte Corporation
      08/01/20234:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INCYIncyte Corporation
      08/01/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
      08/01/20237:00AMBusiness WireIncyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
      07/31/20234:01PMBusiness WireReplimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell CarcinomaNASDAQ:INCYIncyte Corporation
      07/24/20237:00AMPR Newswire (US)Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
      07/18/20234:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/18/20234:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
      07/18/20234:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY